» Articles » PMID: 34985375

Chrysin Impairs Genomic Stability by Suppressing DNA Double-strand Break Repair in Breast Cancer Cells

Overview
Journal Cell Cycle
Specialty Cell Biology
Date 2022 Jan 5
PMID 34985375
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Chrysin, a natural compound isolated from various plants, such as the blue passion flower (.), exhibits multiple pharmacological activities, such as antitumor, anti-inflammatory and antioxidant activities. Accumulating evidence shows that chrysin inhibits cancer cell growth by inducing apoptosis and regulating cell cycle arrest. However, whether chrysin is involved in regulating genomic stability and its underlying mechanisms in breast cancer cells have not been determined. Here, we demonstrated that chrysin impairs genomic stability in MCF-7 and BT474 cells, inhibits cell survival and enhances the sensitivity of MCF-7 cells to chemotherapeutic drugs. Further experiments revealed that chrysin impairs DNA double-strand break (DSB) repair, resulting in accumulation of DNA damage. Mechanistic studies showed that chrysin inhibits the recruitment of the key NHEJ factor 53BP1 and delays the recruitment of the HR factor RAD51. Thus, we elucidated novel regulatory mechanisms of chrysin in DSB repair and proposed that a combination of chrysin and chemotherapy has curative potential in breast cancers.

Citing Articles

Advancements and recent explorations of anti-cancer activity of chrysin: from molecular targets to therapeutic perspective.

Sood A, Mehrotra A, Sharma U, Aggarwal D, Singh T, Shahwan M Explor Target Antitumor Ther. 2024; 5(3):477-494.

PMID: 38966181 PMC: 11220305. DOI: 10.37349/etat.2024.00230.


Chrysin-Induced Regression of Angiogenesis via an Induction of DNA Damage Response and Oxidative Stress in In Vitro and In Vivo Models of Melanoma.

Sassi A, Fredon M, Cotte A, Fuselier C, Schneider C, Martiny L Cells. 2023; 12(12).

PMID: 37371032 PMC: 10297291. DOI: 10.3390/cells12121561.


DNA repair pathways in breast cancer: from mechanisms to clinical applications.

Tufail M Breast Cancer Res Treat. 2023; 200(3):305-321.

PMID: 37289340 DOI: 10.1007/s10549-023-06995-z.


Recent Advances in Pharmaceutical Cocrystals: A Focused Review of Flavonoid Cocrystals.

Xu J, Shi Q, Wang Y, Wang Y, Xin J, Cheng J Molecules. 2023; 28(2).

PMID: 36677670 PMC: 9861466. DOI: 10.3390/molecules28020613.


Tackling heterogeneity in treatment-resistant breast cancer using a broad-spectrum therapeutic approach.

Lowe L, LaValley J, Felsher D Cancer Drug Resist. 2023; 5(4):917-925.

PMID: 36627896 PMC: 9771755. DOI: 10.20517/cdr.2022.40.

References
1.
ODriscoll M, Jeggo P . The role of double-strand break repair - insights from human genetics. Nat Rev Genet. 2005; 7(1):45-54. DOI: 10.1038/nrg1746. View

2.
Schultz L, Chehab N, Malikzay A, Halazonetis T . p53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks. J Cell Biol. 2001; 151(7):1381-90. PMC: 2150674. DOI: 10.1083/jcb.151.7.1381. View

3.
Fradet-Turcotte A, Canny M, Escribano-Diaz C, Orthwein A, Leung C, Huang H . 53BP1 is a reader of the DNA-damage-induced H2A Lys 15 ubiquitin mark. Nature. 2013; 499(7456):50-4. PMC: 3955401. DOI: 10.1038/nature12318. View

4.
Botuyan M, Lee J, Ward I, Kim J, Thompson J, Chen J . Structural basis for the methylation state-specific recognition of histone H4-K20 by 53BP1 and Crb2 in DNA repair. Cell. 2006; 127(7):1361-73. PMC: 1804291. DOI: 10.1016/j.cell.2006.10.043. View

5.
Zhang S, Wang X, Sagawa K, Morris M . Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice. Drug Metab Dispos. 2004; 33(3):341-8. DOI: 10.1124/dmd.104.002501. View